Anti-CGRP antagonist antibodies that block or decrease cAMP activation are disclosed. These are useful in methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes.